文献速递产科

剖宫产术中胎盘部位局部应用重组活化凝血因子VII治疗前置胎盘

Topical application of recombinant activated factor VII during cesarean delivery for placenta previa.
PubMed 文献 · Am J Obstet Gynecol · 2017-02-20

研究纳入5例因前置胎盘行计划性剖宫产的产妇,胎盘娩出后将浸泡于重组活化凝血因子VII盐水溶液(1 mg/246 mL)的拭子敷于胎盘部位2分钟,出血未充分减少时重复一次。全部5例在近乎干燥条件下关闭子宫切口,中位失血量490 mL(范围300–800 mL),未观察到不良反应,外周血凝血指标无显著变化。

要点

  • 前置胎盘剖宫产胎盘娩出后,胎盘部位局部应用重组活化凝血因子VII可能减少出血。
  • 5例中位失血量490 mL(范围300–800 mL),子宫切口均在近乎干燥条件下关闭。
  • 未观察到不良反应,外周血凝血酶生成、纤维蛋白原、活化部分凝血活酶时间、国际标准化比值及血小板计数均无显著变化。

核心结论

  • 本研究表明,前置胎盘患者局部应用重组活化凝血因子VII可能减少胎盘部位出血,且不启动全身凝血。

研究设计与样本

  • 研究纳入5例因前置胎盘行计划性剖宫产的产妇,为病例系列研究。
  • 胎盘娩出后,术者将浸泡于重组活化凝血因子VII盐水溶液(1 mg溶于246 mL)的拭子敷于胎盘部位2分钟,出血未充分减少时重复一次。
  • 另检测5例因其他原因行计划性剖宫产产妇的凝血指标作为对照,采用Mann-Whitney检验分析非配对数据。

主要发现

  • 全部5例均在近乎干燥条件下关闭子宫切口,中位失血量为490 mL(范围300–800 mL)。
  • 未观察到重组活化凝血因子VII的不良反应,未检测到其进入循环。
  • 外周循环中凝血酶生成、纤维蛋白原、活化部分凝血活酶时间、国际标准化比值及血小板计数均无变化(所有P值>.20)。

临床怎么用

  • 作者认为,前置胎盘患者胎盘部位局部应用重组活化凝血因子VII可能减少出血且不启动全身凝血。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: During cesarean delivery in patients with placenta previa, hemorrhaging after removal of the placenta is often challenging. In this condition, the extraordinarily high concentration of tissue factor at the placenta site may constitute a principle of treatment as it activates coagulation very effectively. The presumption, however, is that tissue factor is bound to activated factor VII. OBJECTIVE: We hypothesized that topical application of recombinant activated factor VII at the placenta site reduces bleeding without affecting intravascular coagulation. STUDY DESIGN: We included 5 cases with planned cesarean delivery for placenta previa. After removal of the placenta, the surgeon applied a swab soaked in recombinant activated factor VII containing saline (1 mg in 246 mL) to the placenta site for 2 minutes; this treatment was repeated once if the bleeding did not decrease sufficiently. We documented the treatment on video recordings and measured blood loss. Furthermore, we determined hemoglobin concentration, platelet count, international normalized ratio, activated partial thrombin time, fibrinogen (functional), factor VII:clot, and thrombin generation in peripheral blood prior to and 15 minutes after removal of the placenta. We also tested these blood coagulation variables in 5 women with cesarean delivery planned for other reasons. Mann-Whitney test was used for unpaired data. RESULTS: In all 5 cases, the uterotomy was closed under practically dry conditions and the median blood loss was 490 (range 300-800) mL. There were no adverse effects of recombinant activated factor VII and we did not measure factor VII to enter the circulation. Neither did we observe changes in thrombin generation, fibrinogen, activated partial thrombin time, international normalized ratio, and platelet count in the peripheral circulation (all P values >.20). CONCLUSION: This study indicates that in patients with placenta previa, topical recombinant activated factor VII may diminish bleeding from the placenta site without initiation of systemic coagulation.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Schjoldager BTBG, Mikkelsen E, Lykke MR, et al. Topical application of recombinant activated factor VII during cesarean delivery for placenta previa. Am J Obstet Gynecol. 2017. PMID: 28219621. doi:10.1016/j.ajog.2017.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。